Literature DB >> 11153915

Association between CYP1A2 polymorphism and susceptibility to porphyria cutanea tarda.

L Christiansen1, A Bygum, A Jensen, K Thomsen, F Brandrup, M Hørder, N E Petersen.   

Abstract

Individuals with the most common form of the porphyrias, porphyria cutanea tarda (PCT), are believed to be genetically predisposed to development of clinically overt disease through mutations and polymorphisms in genes associated with known precipitating factors. In this study, we have examined a group of Danish patients with PCT for the presence of the C/A polymorphism in intron 1 of CYP1A2. The results demonstrate that the frequency of the highly inducible A/A genotype is increased in both familial and sporadic PCT. This suggests that inheritance of this genotype is a susceptibility factor in development of PCT.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11153915     DOI: 10.1007/s004390000415

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  24 in total

1.  CYP1A2 is essential in murine uroporphyria caused by hexachlorobenzene and iron.

Authors:  P R Sinclair; N Gorman; H S Walton; W J Bement; T P Dalton; J F Sinclair; A G Smith; D W Nebert
Journal:  Toxicol Appl Pharmacol       Date:  2000-01-01       Impact factor: 4.219

2.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

3.  Inhibition of uroporphyrinogen decarboxylase activity. The role of cytochrome P-450-mediated uroporphyrinogen oxidation.

Authors:  R W Lambrecht; J M Jacobs; P R Sinclair; J F Sinclair
Journal:  Biochem J       Date:  1990-07-15       Impact factor: 3.857

4.  A population and family study of CYP1A2 using caffeine urinary metabolites.

Authors:  A Catteau; Y C Bechtel; N Poisson; P R Bechtel; C Bonaïti-Pellie
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

5.  Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans.

Authors:  M Nakajima; T Yokoi; M Mizutani; M Kinoshita; M Funayama; T Kamataki
Journal:  J Biochem       Date:  1999-04       Impact factor: 3.387

Review 6.  Uroporphyrinogen decarboxylase.

Authors:  G H Elder; A G Roberts
Journal:  J Bioenerg Biomembr       Date:  1995-04       Impact factor: 2.945

7.  Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America.

Authors:  H L Bonkovsky; M Poh-Fitzpatrick; N Pimstone; J Obando; A Di Bisceglie; C Tattrie; K Tortorelli; P LeClair; M G Mercurio; R W Lambrecht
Journal:  Hepatology       Date:  1998-06       Impact factor: 17.425

8.  Chemically-induced formation of an inhibitor of hepatic uroporphyrinogen decarboxylase in inbred mice with iron overload.

Authors:  A G Smith; J E Francis
Journal:  Biochem J       Date:  1987-08-15       Impact factor: 3.857

9.  Uroporphyria produced in mice by 20-methylcholanthrene and 5-aminolaevulinic acid.

Authors:  A J Urquhart; G H Elder; A G Roberts; R W Lambrecht; P R Sinclair; W J Bement; N Gorman; J A Sinclair
Journal:  Biochem J       Date:  1988-07-15       Impact factor: 3.857

10.  Haem synthesis from exogenous 5-aminolaevulinate in cultured chick-embryo hepatocytes. Effects of inducers of cytochromes P-450.

Authors:  S I Shedlofsky; P R Sinclair; H L Bonkovsky; J F Healey; A T Swim; J M Robinson
Journal:  Biochem J       Date:  1987-11-15       Impact factor: 3.857

View more
  7 in total

1.  The effect of the CYP1A2 *1F mutation on CYP1A2 inducibility in pregnant women.

Authors:  Anna Nordmark; Stefan Lundgren; Birgitta Ask; Fredrik Granath; Anders Rane
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

Review 2.  Porphyrias at a glance: diagnosis and treatment.

Authors:  Maria Domenica Cappellini; Valentina Brancaleoni; Giovanna Graziadei; Dario Tavazzi; Elena Di Pierro
Journal:  Intern Emerg Med       Date:  2010-10       Impact factor: 3.397

3.  CYP2D6 polymorphisms in patients with porphyrias.

Authors:  Jimena V Lavandera; Victoria E Parera; Alcira Batlle; Ana María Buzaleh
Journal:  Mol Med       Date:  2006 Sep-Oct       Impact factor: 6.354

Review 4.  Rapid genotyping for relevant CYP1A2 alleles by pyrosequencing.

Authors:  Carsten Skarke; Anja Kirchhof; Gerd Geisslinger; Jörn Lötsch
Journal:  Eur J Clin Pharmacol       Date:  2005-11-24       Impact factor: 2.953

5.  Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer.

Authors:  Donghui Li; Li Jiao; Yanan Li; Mark A Doll; David W Hein; Melissa L Bondy; Douglas B Evans; Robert A Wolff; Renato Lenzi; Peter W Pisters; James L Abbruzzese; Manal M Hassan
Journal:  Carcinogenesis       Date:  2005-06-29       Impact factor: 4.944

6.  CYP1A2*1F and GSTM1 alleles are associated with susceptibility to porphyria cutanea tarda.

Authors:  Jeffrey K Wickliffe; Sherif Z Abdel-Rahman; Chul Lee; Csilla Kormos-Hallberg; Gagan Sood; Catherine M Rondelli; James J Grady; Robert J Desnick; Karl E Anderson
Journal:  Mol Med       Date:  2010-10-15       Impact factor: 6.354

7.  High penetrance of acute intermittent porphyria in a Spanish founder mutation population and CYP2D6 genotype as a susceptibility factor.

Authors:  María Barreda-Sánchez; Juan Buendía-Martínez; Guillermo Glover-López; Carmen Carazo-Díaz; María Juliana Ballesta-Martínez; Vanesa López-González; María José Sánchez-Soler; Lidya Rodriguez-Peña; Ana Teresa Serrano-Antón; Remedios Gil-Ferrer; Maria Del Carmen Martínez-Romero; Pablo Carbonell-Meseguer; Encarna Guillén-Navarro
Journal:  Orphanet J Rare Dis       Date:  2019-02-26       Impact factor: 4.123

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.